BOSTON--(BUSINESS WIRE)--March 7, 2006--Proteome Systems Ltd (ASX:PXL) today announced the signing of an agreement with the New York-based biotechnology company, Egenix Inc. to co-develop a semen-based diagnostic kit for prostate cancer based on the known proprietary Human Carcinoma Antigen (HCA).
